ChemImage announced that it has been selected to receive up to $1 million in funding from the Ohio Third Frontier Advanced Materials Program. The award will be used to establish a manufacturing facility for its multi-conjugate filter technology.
Abbott announced the initiation of ABSORB BTK, a clinical trial evaluating the safety and efficacy of the Absorb bioresorbable vascular scaffold for the treatment of below-the-knee critical limb ischemia.
Ardea Biosciences Inc. has reached an agreement with the Food and Drug Administration on clinical trials of lesinurad, including the size and design of the studies, their main goals, the safety databases, and manufacturing plans.
Hi-Tech Pharmacal Co. Inc. said its fiscal first-quarter profit climbed 59%, helped by generic drug sales gains. The Amityville, N.Y., company earned $13.8 million in the three months that ended July 31.
Procter & Gamble Co. expects sales in big emerging markets to help offset sluggish sales in the United States and other developed countries. He sees huge potential for expanding P&G health care product sales from a partnership with Teva Pharmaceutical Industries.
A new anticlotting drug that had been seen as a blockbuster comes under scrutiny by a panel of outside advisers to the Food and Drug Administration, two days after a negative review by FDA staff.
Traditionally, synthesis of peptides has been done via liquid- or solid-phase processes. A convergent methodology of peptide synthesis that can produce historically challenging peptides using a consistent process from R&D to commercialization is described.
PerkinElmer, Inc. signed a definitive agreement to acquire Caliper Life Sciences, Inc. for $10.50 per share, for a total net purchase price of approximately $600 million.
Scientists have discovered a biological switch that gives energy-storing white fat the characteristics of energy-burning brown fat.
Noxxon Pharma announced the initiation of a Phase 1 clinical trial for NOX-H94, the company’s third compound to enter the clinic.
European regulators have approved the Johnson & Johnson pill Zytiga as a treatment for men with advanced prostate cancer who have already undergone chemotherapy.
Starting with normal skin cells, scientists from The Scripps Research Institute have produced the first stem cells from endangered species.
Royalty Pharma refinanced $2.75 billion of outstanding debt and funded a one-time $850 million cash distribution to shareholders.
Every day, we purge 100 to 200 billion dead or dying cells – a process called cell clearance, which is fundamental in our ability to maintain a healthy physiological balance and prevent a number of chronic diseases.